G1 Therapeutics (NASDAQ:GTHX) was upgraded by investment analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Wednesday.
A number of other equities analysts have also recently weighed in on GTHX. Zacks Investment Research raised G1 Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. BTIG Research initiated coverage on G1 Therapeutics in a research note on Tuesday, December 19th. They issued a “buy” rating and a $38.00 target price for the company. JPMorgan Chase & Co. upped their target price on G1 Therapeutics to $30.00 in a research note on Monday, February 5th. Finally, Cowen reiterated a “buy” rating on shares of G1 Therapeutics in a research note on Wednesday, November 8th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. G1 Therapeutics currently has an average rating of “Buy” and an average price target of $32.80.
G1 Therapeutics (GTHX) opened at $23.87 on Wednesday. G1 Therapeutics has a 1-year low of $12.04 and a 1-year high of $28.67.
In related news, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $19.75, for a total value of $3,950,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Rajesh Malik sold 3,776 shares of the company’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $22.96, for a total value of $86,696.96. The disclosure for this sale can be found here. Insiders sold 216,552 shares of company stock valued at $4,294,504 over the last quarter.
A number of hedge funds have recently bought and sold shares of GTHX. BlackRock Inc. grew its position in G1 Therapeutics by 113.5% during the fourth quarter. BlackRock Inc. now owns 745,445 shares of the company’s stock valued at $14,790,000 after acquiring an additional 396,215 shares during the period. Franklin Resources Inc. grew its position in G1 Therapeutics by 10.1% during the fourth quarter. Franklin Resources Inc. now owns 1,535,616 shares of the company’s stock valued at $30,467,000 after acquiring an additional 141,000 shares during the period. Vanguard Group Inc. purchased a new stake in G1 Therapeutics during the second quarter valued at about $1,291,000. Goldman Sachs Group Inc. purchased a new stake in G1 Therapeutics during the second quarter valued at about $1,144,000. Finally, Two Sigma Investments LP purchased a new stake in G1 Therapeutics during the fourth quarter valued at about $493,000. 52.01% of the stock is owned by hedge funds and other institutional investors.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.